 Genetic Therapy
"Genetic Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions.
| Descriptor ID |
D015316
|
| MeSH Number(s) |
E02.095.301 E05.393.420.301
|
| Concept/Terms |
Genetic Therapy- Genetic Therapy
- Genetic Therapies
- Therapies, Genetic
- Therapy, Genetic
- Therapy, DNA
- DNA Therapy
Genetic Therapy, Somatic- Genetic Therapy, Somatic
- Genetic Therapies, Somatic
- Somatic Genetic Therapies
- Somatic Genetic Therapy
- Therapies, Somatic Genetic
- Therapy, Somatic Genetic
Genetic Therapy, Gametic- Genetic Therapy, Gametic
- Gametic Genetic Therapies
- Gametic Genetic Therapy
- Genetic Therapies, Gametic
- Therapies, Gametic Genetic
- Therapy, Gametic Genetic
|
Below are MeSH descriptors whose meaning is more general than "Genetic Therapy".
Below are MeSH descriptors whose meaning is more specific than "Genetic Therapy".
This graph shows the total number of publications written about "Genetic Therapy" by people in this website by year, and whether "Genetic Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 5 | 1 | 6 | | 1997 | 3 | 5 | 8 | | 1998 | 4 | 1 | 5 | | 1999 | 2 | 5 | 7 | | 2000 | 5 | 4 | 9 | | 2001 | 3 | 3 | 6 | | 2002 | 6 | 4 | 10 | | 2003 | 6 | 8 | 14 | | 2004 | 5 | 2 | 7 | | 2005 | 7 | 5 | 12 | | 2006 | 3 | 6 | 9 | | 2007 | 7 | 3 | 10 | | 2008 | 10 | 5 | 15 | | 2009 | 9 | 3 | 12 | | 2010 | 1 | 3 | 4 | | 2011 | 4 | 3 | 7 | | 2012 | 4 | 1 | 5 | | 2013 | 1 | 4 | 5 | | 2014 | 8 | 8 | 16 | | 2015 | 1 | 5 | 6 | | 2016 | 2 | 6 | 8 | | 2017 | 4 | 1 | 5 | | 2018 | 6 | 3 | 9 | | 2019 | 3 | 6 | 9 | | 2020 | 6 | 3 | 9 | | 2021 | 6 | 4 | 10 | | 2022 | 2 | 3 | 5 | | 2023 | 1 | 11 | 12 | | 2024 | 7 | 3 | 10 | | 2025 | 5 | 4 | 9 | | 2026 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Genetic Therapy" by people in Profiles.
-
Calton MA, Croze RH, Sullivan TH, Collins SA, Tucker S, Whittlesey KJ, Kim DH, Nye JA, Beliakoff G, Quezada M, Burns C, Schmitt C, Klein A, Jia V, Kovacs L, Lauko D, Yoh K, Nguyen K, Barglow K, Gonzales J, Khoday D, Mason T, Delaria K, Bashour K, Kotterman M, Schaffer D, Song A, Francis P, Taylor-Cousar JL, Kirn D. Design and characterization of 4D-710, an aerosolized gene therapy for cystic fibrosis lung disease. Am J Respir Cell Mol Biol. 2026 Jul 01; 74(7):837-846.
-
Crooke ST, Glass S, Gleeson JG, Mignon L, Skourti-Stathaki K, Douville J, Knutsen M, Pu H, Bain JM, Berry-Kravis E, Shneider NA, Kim-McManus O, Eichler FS, Chung WK, Nagy A, Kaufmann H, Gonzalez-Duarte A, Oskarsson B, McCourt EA, Leung N. Addressing the needs of nano-rare patients: the n-Lorem experience. Nucleic Acids Res. 2026 May 20; 54(10).
-
Palomba ML, Schuster SJ, Karmali R, Skarbnik AP, Abramson JS, Ardeshna K, Borchmann P, Hill BT, García-Sancho AM, Marcacci G, Rapoport AP, Cartron G, Fleury I, Izutsu K, Kamdar M, Mielke S, Barbui AM, Ortega JLR, Nastoupil LJ, Ahmed S, Bar M, Diaz L, Furustrand U, Diab V, Vedal M, Avilion A, Kumar J, Nishii R, Colicino S, Morschhauser F. Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study. Lancet. 2026 Mar 07; 407(10532):963-975.
-
Spira AI, Berz D, Jotte RM, Pachipala KK, Berger MS. Dose Escalation Trial of the Combination of Osimertinib and Quaratusugene Ozeplasmid Gene Therapy in Patients with Advanced NSCLC. Clin Lung Cancer. 2026 Jan; 27(1):75-81.
-
Wang S, Zhang P, Sun Y, Fang Y, Wang P, Shao M, Zhang N, Shi S, Chen X, Gao H, Cheng J, Gao B, Liu T, Qian Q, Song C. Engineering of BZ transposase and transposon donor vector for enhanced efficiency and safety in gene delivery applications. Nucleic Acids Res. 2025 Sep 23; 53(18).
-
Tamura S, Nelson AD, Spratt PWE, Hamada EC, Zhou X, Kyoung H, Li Z, Arnould C, Barskyi V, Krupkin B, Young K, Zhao J, Holden SS, Sahagun A, Keeshen CM, Lu C, Ben-Shalom R, Taloma SE, Schamiloglu S, Li YC, Min L, Jenkins PM, Pan JQ, Paz JT, Sanders SJ, Matharu N, Ahituv N, Bender KJ. CRISPR activation for SCN2A-related neurodevelopmental disorders. Nature. 2025 10; 646(8086):983-991.
-
Wolff JM, Capocci N, Atas E, Bharucha-Goebel DX, Brandsema JF, Butterfield RJ, Chadwick CB, Corti M, Crawford TO, Cripe L, Day JW, Duong T, ElMallah MK, Flanigan KM, George LA, Goedeker NL, Goude E, Hesterlee S, Lin B, Katz NK, Matesanz SE, McDonald C, McNally EM, Mercado-Rodriguez C, Nandi D, Parsons JA, Proud C, Ramos-Platt L, Lek A, Salabarria SM, Camino E, Schrader R, Shea E, Shell R, Shieh PB, Soslow JH, Taylor JB, Veerapandiyan A, Villa C, Yang ML, Zaidman CM, Leon-Astudillo C, Byrne BJ. Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy. Neuromuscul Disord. 2025 Sep; 54:106208.
-
Ibel A, Bhardwaj R, Yilmaz DE, Kong S, Wendlinger S, Cordero C, Papaioannou D, Papazian M, Schönauer R, Meng Q, Eckardt KU, Hassan F, Volpe I, Klämbt V, Halbritter J, Fedeles S, Krappitz M, Kaminski MM. In vivo base editing reduces liver cysts in autosomal dominant polycystic kidney disease. Mol Ther. 2025 Nov 05; 33(11):5373-5382.
-
Mayer-Hamblett N, Kerper NR, Clancy JP, Davies JC, Taylor-Cousar JL, Donaldson SH, Bell SC, Jain R, Simmonds NJ, Mall MA, Goss CH, Rayment JH, Setiawan L, Pilewski JM. Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trials. Lancet Respir Med. 2025 Dec; 13(12):1108-1118.
-
Cheerie D, Meserve MM, Beijer D, Kaiwar C, Newton L, Taylor Tavares AL, Verran AS, Sherrill E, Leonard S, Sanders SJ, Blake E, Elkhateeb N, Gandhi A, Liang NSY, Morgan JT, Verwillow A, Verheijen J, Giles A, Williams S, Chopra M, Croft L, Dafsari HS, Davidson AE, Friedman J, Gregor A, Haque B, Lechner R, Montgomery KA, Ryten M, Schober E, Siegel G, Sullivan PJ, Whittle EF, Zardetto B, Yu TW, Synofzik M, Aartsma-Rus A, Costain G, Lauffer MC. Consensus guidelines for assessing eligibility of pathogenic DNA variants for antisense oligonucleotide treatments. Am J Hum Genet. 2025 05 01; 112(5):975-983.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|